Maravai LifeSciences
MRVI
178 hedge funds and large institutions have $876M invested in Maravai LifeSciences in 2026 Q2 according to their latest regulatory filings, with 45 funds opening new positions, 56 increasing their positions, 54 reducing their positions, and 23 closing their positions.
395% more call options, than puts
Call options by funds: $4.51M | Put options by funds: $910K
155% more capital invested
Capital invested by funds: $344M → $876M (+$532M)
96% more first-time investments, than exits
New positions opened: 45 | Existing positions closed: 23
13% more funds holding
Funds holding: 158 → 178 (+20)
12.18% more ownership
Funds ownership: 82.95% → 95.13% (+12%)
4% more repeat investments, than reductions
Existing positions increased: 56 | Existing positions reduced: 54
0% more funds holding in top 10
Funds holding in top 10: 4 → 4 (0)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
+$21M |
| 2 |
OAM
Ophir Asset Management
Sydney,
Australia
|
+$20.8M |
| 3 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
+$14.9M |
| 4 |
Nuveen
Charlotte,
North Carolina
|
+$11.3M |
| 5 |
JP Morgan Chase
New York
|
+$9.65M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Mackenzie Financial
Toronto Ontario,
Ontario, Canada
|
-$17.8M |
| 2 |
TC
Tejara Capital
London,
United Kingdom
|
-$8.2M |
| 3 |
B
Braidwell
Stamford,
Connecticut
|
-$6.64M |
| 4 |
Jane Street
New York
|
-$6.45M |
| 5 |
Morgan Stanley
New York
|
-$6.09M |
MRVI Hedge Fund Activity: Q2 2026 in Review
178 of the 8,317 institutional investors tracked by Wall St. Rank reported a position in Maravai LifeSciences (MRVI) for Q2 2026, worth a combined $876M — up 155% from $344M a quarter earlier.
Buyers outnumbered sellers: 45 funds opened new MRVI positions and 23 closed out — a net gain of 22 holders — while 56 added to existing stakes and 54 trimmed.
The largest buyer was Millennium Management, adding an estimated $21M. The largest seller was Mackenzie Financial, exiting entirely with an estimated $17.8M sold.
- 178 institutional investors held Maravai LifeSciences (MRVI) as of Q2 2026, up from 158 in Q1 2026.
- Funds reported $876M of Maravai LifeSciences stock for Q2 2026, up 155% quarter-over-quarter.
- 45 funds opened new Maravai LifeSciences positions in Q2 2026 and 23 closed out, a net change of +22 holders.
- The largest Maravai LifeSciences buyer in Q2 2026 was Millennium Management, an estimated $21M added.
- The largest Maravai LifeSciences seller in Q2 2026 was Mackenzie Financial, an estimated $17.8M sold.
Based on aggregated 13F filings for Q2 2026.